Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 8 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Global Markets Direct Report Coverage | 10 | 1 |
| Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Overview | 11 | 1 |
| Therapeutics Development | 12 | 4 |
| Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Products under Development by Stage of Development | 12 | 1 |
| Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Products under Development by Therapy Area | 13 | 1 |
| Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Products under Development by Indication | 14 | 2 |
| Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Pipeline Products Glance | 16 | 2 |
| Late Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Products under Development by Companies | 18 | 8 |
| Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Products under Development by Universities/Institutes | 26 | 2 |
| Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Therapeutics Assessment | 28 | 5 |
| Assessment by Monotherapy/Combination Products | 28 | 1 |
| Assessment by Mechanism of Action | 29 | 1 |
| Assessment by Route of Administration | 30 | 1 |
| Assessment by Molecule Type | 31 | 2 |
| Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Companies Involved in Therapeutics Development | 33 | 22 |
| AbbVie Inc | 33 | 2 |
| ACEA Biosciences, Inc. | 35 | 1 |
| Advinus Therapeutics Ltd | 36 | 1 |
| ArQule, Inc. | 37 | 1 |
| BeiGene, Ltd. | 38 | 1 |
| Beijing Hanmi Pharmaceutical Co Ltd | 39 | 1 |
| Biogen Inc | 40 | 1 |
| Bristol-Myers Squibb Company | 41 | 1 |
| Celgene Corporation | 42 | 1 |
| CrystalGenomics, Inc. | 43 | 1 |
| Genentech, Inc. | 44 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 45 | 1 |
| LSK BioPartners, Inc. | 46 | 1 |
| Merck KGaA | 47 | 1 |
| Ono Pharmaceutical Co., Ltd. | 48 | 1 |
| Pharmacyclics, Inc. | 49 | 1 |
| Principia Biopharma Inc. | 50 | 1 |
| Redx Pharma Plc | 51 | 1 |
| Simcere Pharmaceutical Group | 52 | 1 |
| Sunesis Pharmaceuticals, Inc. | 53 | 1 |
| Takeda Pharmaceutical Company Limited | 54 | 1 |
| Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Drug Profiles | 55 | 72 |
| ABBV-599 Drug Profile | 55 | 1 |
| AC-058 Drug Profile | 56 | 1 |
| acalabrutinib Drug Profile | 57 | 3 |
| Antisense Oligonucleotides to Activate BTK for X-linked Agammaglobulinemia Drug Profile | 60 | 1 |
| ARQ-531 Drug Profile | 61 | 1 |
| BGB-3111 Drug Profile | 62 | 3 |
| BIIB-068 Drug Profile | 65 | 1 |
| BMS-986142 Drug Profile | 66 | 1 |
| BMS-986195 Drug Profile | 67 | 1 |
| CG-026806 Drug Profile | 68 | 1 |
| CG-036806 Drug Profile | 69 | 1 |
| Drug to Inhibit BTK for Undisclosed Indications Drug Profile | 70 | 1 |
| DTRMWXHS-12 Drug Profile | 71 | 1 |
| EBI-1266 Drug Profile | 72 | 1 |
| EBI-1367 Drug Profile | 73 | 1 |
| HCI-1401 Drug Profile | 74 | 1 |
| HCI-1684 Drug Profile | 75 | 1 |
| HM-71224 Drug Profile | 76 | 1 |
| ibrutinib Drug Profile | 77 | 23 |
| M-2951 Drug Profile | 100 | 1 |
| M-7583 Drug Profile | 101 | 1 |
| ONO-4059 Drug Profile | 102 | 2 |
| PLS-123 Drug Profile | 104 | 1 |
| PNQ-154 Drug Profile | 105 | 1 |
| PNQ-849 Drug Profile | 106 | 1 |
| PRN-1008 Drug Profile | 107 | 2 |
| PRN-473 Drug Profile | 109 | 1 |
| RDX-002 Drug Profile | 110 | 1 |
| RG-7845 Drug Profile | 111 | 1 |
| Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis Drug Profile | 112 | 1 |
| Small Molecule to Inhibit BTK and IRAK4 for Autoimmune Disorders and Rheumatoid Arthritis Drug Profile | 113 | 1 |
| Small Molecule to Inhibit BTK for Immunology Drug Profile | 114 | 1 |
| Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer Drug Profile | 115 | 1 |
| Small Molecule to Inhibit BTK for Oncology Drug Profile | 116 | 1 |
| Small Molecule to Target BTK for Immunology Drug Profile | 117 | 1 |
| Small Molecules to Inhibit BTK for Oncology Drug Profile | 118 | 1 |
| Small Molecules to Inhibit BTK for Rheumatoid Arthritis Drug Profile | 119 | 2 |
| SNS-062 Drug Profile | 121 | 2 |
| spebrutinib besylate Drug Profile | 123 | 2 |
| TAK-020 Drug Profile | 125 | 1 |
| X-022 Drug Profile | 126 | 1 |
| Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Dormant Projects | 127 | 3 |
| Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Discontinued Products | 130 | 1 |
| Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Featured News &Press Releases | 131 | 12 |
| Oct 07, 2016: BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenstrom s Macroglobulinemia at 9th International Workshop on Waldenstrom s Macroglobulinemia | 131 | 1 |
| Sep 26, 2016: AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA) for Treatment of Marginal Zone Lymphoma | 132 | 1 |
| Sep 12, 2016: Sunesis Presents Dose Escalation Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062 | 132 | 1 |
| Sep 01, 2016: Sunesis Pharmaceuticals Announces Poster Presentation on Preliminary Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 at the European School of Haematology s 2nd International Conferenc... | 133 | 1 |
| Aug 09, 2016: First-in-class treatment now available for some patients in Scotland with rare, aggressive and incurable blood cancers | 134 | 1 |
| Jul 21, 2016: CHMP adopts extension to existing therapeutic indication for Imbruvica | 134 | 1 |
| Jul 20, 2016: Health Canada Approves IMBRUVICA (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia | 135 | 1 |
| Jul 18, 2016: ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference | 136 | 1 |
| Jul 05, 2016: BeiGene Announces First Patient Dosing for Investigational BTK Inhibitor BGB-3111 in China | 137 | 1 |
| Jun 29, 2016: AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration for Ibrutinib (IMBRUVICA) for Chronic Graft-Versus-Host-Disease, a Rare Condition with Limited Treatment Options | 137 | 1 |
| Jun 29, 2016: BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317 | 138 | 1 |
| Jun 21, 2016: Aptose Biosciences Provides Update on Leukemia Drug CG 806 | 138 | 1 |
| Jun 08, 2016: Bristol-Myers Squibb Announces Data on BMS-986142 at the Annual European Congress of Rheumatology (EULAR 2016) | 139 | 1 |
| Jun 06, 2016: AbbVie Builds Upon Robust Body of IMBRUVICA (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology Annual Meeting | 139 | 2 |
| Jun 01, 2016: NICE asks company to put leukaemia drug forward for new Cancer Drugs Fund | 141 | 2 |
| Appendix | 143 | 2 |
| Methodology | 143 | 1 |
| Coverage | 143 | 1 |
| Secondary Research | 143 | 1 |
| Primary Research | 143 | 1 |
| Expert Panel Validation | 143 | 1 |
| Contact Us | 143 | 1 |
| Disclaimer | 144 | 1 |
